



ORIGINAL ARTICLE

Factors associated with vasoplegic shock in the postoperative period of cardiac surgery and influence on morbidity and mortality of the use of arginine vasopressin as rescue therapy



María Barrera Sánchez, Cristina Royo Villa, Pablo Ruiz de Gopegui Miguelena*, Pablo Gutiérrez Ibañes, Andrés Carrillo López

Hospital Universitario Miguel Servet, Zaragoza, Spain

Received 2 January 2024; accepted 11 March 2024

Available online 1 May 2024

KEYWORDS

Vasoplegic syndrome;
Cardiac surgery;
Cardio-pulmonary
bypass;
Norepinephrine;
Vasopressin

Abstract

Objectives: Analyzing associated factors with vasoplegic shock in the postoperative period of Cardiac Surgery. Analyzing the influence of vasopressin as rescue therapy to first-line treatment with norepinephrine.

Design: Cohort, prospective and observational study.

Setting: Main hospital Postoperative Cardiac ICU.

Patients: Patients undergoing cardiac surgery with subsequent ICU admission from January 2021 to December 2022.

Interventions: Record of presurgical, perioperative and ICU discharge clinical variables.

Main variables of interest: chronic treatment, presence of vasoplegic shock, need for vasopressin, cardiopulmonary bypass time, mortality.

Results: 773 patients met the inclusion criteria. The average age was 67.3, with predominance of males (65.7%). Post-CPB vasoplegia was documented in 94 patients (12.2%). In multivariate analysis, vasoplegia was associated with age, female sex, presurgical creatinine levels, cardiopulmonary bypass time, lactate level upon admission to the ICU, and need for prothrombin complex transfusion. Of the patients who developed vasoplegia, 18 (19%) required rescue vasopressin, associated with pre-surgical intake of ACEIs/ARBs, worse Euroscore score and longer cardiopulmonary bypass time. Refractory vasoplegia with vasopressin requirement was associated with increased morbidity and mortality.

DOI of original article: <https://doi.org/10.1016/j.medin.2024.03.005>

* Corresponding author.

E-mail address: pruizdegopegui@salud.aragon.es (P. Ruiz de Gopegui Miguelena).

2173-5727/© 2024 Elsevier España, S.L.U. and SEMICYUC. All rights reserved.

PALABRAS CLAVE

Síndrome vasopléjico;
Cirugía cardíaca;
Bypass
cardiopulmonar;
Noradrenalina;
Vasopresina

Conclusions: Postcardiopulmonary bypass vasoplegia is associated with increased mortality and morbidity. Shortening cardiopulmonary bypass times and minimizing products blood transfusion could reduce its development. Removing ACEIs and ARBs prior to surgery could reduce the incidence of refractory vasoplegia requiring rescue with vasopressin. The first-line treatment is norepinephrine and rescue treatment with VSP is a good choice in refractory situations. The first-line treatment of this syndrome is norepinephrine, although rescue with vasopressin is a good complement in refractory situations.

© 2024 Elsevier España, S.L.U. and SEMICYUC. All rights reserved.

Factores asociados a shock vasopléjico en el postoperatorio de cirugía cardíaca e influencia en la morbilidad del uso de arginina vasopresina como terapia de rescate

Resumen

Objetivos: Analizar los factores asociados al shock vasopléjico en el postoperatorio de Cirugía Cardíaca. Analizar la influencia de la vasopresina como terapia de rescate al tratamiento de primera línea con noradrenalina.

Diseño: Estudio de cohortes, prospectivo y observacional.

Ámbito: UCI de Postoperatorio Cardíaco de hospital de tercer nivel.

Pacientes: Pacientes sometidos a cirugía cardíaca con ingreso posterior en UCI desde enero de 2021 hasta diciembre de 2022.

Intervenciones: Registro de variables clínicas prequirúrgicas, perioperatorias y al alta de UCI.

Variables de interés principales: Tratamiento crónico, presencia de shock vasopléjico, necesidad de vasopresina, tiempo de circulación extracorpórea, mortalidad.

Resultados: 773 pacientes cumplieron los criterios de inclusión. La edad media fue 67,3 años, predominio del sexo masculino (65,7%). Se documentó vasoplejia postCEC en 94 pacientes (12,2%). La vasoplejia se asoció independientemente con edad, sexo femenino, creatinina prequirúrgica, tiempo de circulación extracorpórea, lactato al ingreso en UCI y necesidad de complejo protrombínico. De los pacientes que desarrollaron vasoplejia, 18 (19%) precisaron vasopresina de rescate, asociándose con la toma prequirúrgica de IECAs/ARAI, peor Euroscore y mayor tiempo de circulación extracorpórea. La vasoplejia refractaria con necesidad de vasopresina se asoció a aumento de morbilidad.

Conclusiones: La vasoplejia post-circulación extracorpórea se asocia a aumento de morbilidad. Acortar tiempos de circulación extracorpórea y minimizar necesidades trasfusionales podrían disminuir su desarrollo. Retirar IECAs y ARAII previa a la cirugía podría reducir la incidencia de vasoplejia refractaria con necesidad de rescate con vasopresina. El tratamiento de primera línea de este síndrome es la noradrenalina, si bien, el rescate con vasopresina es un buen complemento en situaciones de refractariedad.

© 2024 Elsevier España, S.L.U. y SEMICYUC. Todos los derechos reservados.

Introduction

Although extracorporeal circulation (ECC) has revolutionized cardiac surgery, its use is no stranger to vascular (large vessel ruptures and/or dissections), embolic, hemorrhagic (related to anticoagulation), and hemodynamic complications.

Regarding the latter, vasoplegic shock during the immediate postoperative care stands out, defined as systemic arterial hypotension (mean arterial pressure—MAP— <65 mmHg) due to intense vasodilation with loss of systemic vascular resistance (SVR < 800 dynes s/cm²), and a normal or elevated cardiac index (CI > 2.2 L/min/m²). It is characterized by an inappropriate response to usual doses of vasopressor drugs,

occurring between 5% and 25%, and associated with a high mortality rate.^{1,2}

The mechanisms involved are multifactorial and not entirely known, mainly mediated by a disproportionate immune response: release of proinflammatory mediators, complement activation due to surgical aggression, ischemia-reperfusion injury to the heart and lungs, polytransfusion, or blood exposure to exogenous material in the ECC circuit.¹ These factors promote an increase in oxygen-free radicals, endothelins, nitric oxide (NO), platelet activation factors, thromboxane A₂, prostaglandins, and cytokines.³ All of these lead to intense systemic arterial vasodilation, participating in the development of the systemic inflammatory response syndrome (SIRS), which intensifies such

vasodilation.^{1,2} Additionally, this situation triggers a relative decrease in plasma levels of arginine-vasopressin, due to the depletion of the neurohypophyseal vasopressin reserve and an initial release due to the stress caused by the duration of ECC, along with a relative deficit of cortisol and dysfunction of the renin-angiotensin axis.³ This dysfunction is due to decreased production of angiotensin-2 by exclusion of the pulmonary circulation during ECC, thus precipitating vasoplegia.⁵

Parallel to the activation of the aforementioned vasodilatory mechanisms, there is resistance to vasoactive drugs and molecules, especially amines, due to inactivation of cytoplasmic calcium channels.³

The combination of these biochemical and cellular processes generates intense systemic vasodilation, clinically manifested as distributive shock with severe arterial hypotension.

The treatment of this condition has traditionally been based on vasoactive amines (norepinephrine (NAD) or adrenaline), which have a narrow therapeutic margin and are associated with cardiovascular adverse events (arrhythmias and myocardial ischemia) with incidence rates close to 50%.⁶ Furthermore, during the course of vasoplegic shock, smooth muscle cells present in the blood vessels acquire resistance to amines (mainly NAD) through complex mechanisms (activation of potassium channels, increased synthesis of NO, desensitization of adrenoreceptors, and relative deficiency of vasopressin and corticosteroids).^{5,7} In this regard, arginine vasopressin (AVP), a physiological vasopressor hormone, has been proposed as a bailout therapy for in this type of shock.

The objective of our study is to describe the factors associated with the occurrence of post-ECC vasoplegic shock and the impact that the development of refractory vasoplegia and the need for bailout vasopressin has on morbidity and mortality.

Patients and methods

We conducted a retrospective and observational cohort study with successive patients undergoing cardiac surgery at Hospital Miguel Servet, Zaragoza, Spain treated in the intensive care unit from January 1, 2021 through December 31, 2022. The study was approved by the Research Ethics Committee of the Autonomous Community of Aragon. The follow-up period covered the duration of the immediate postoperative care period at the ICU until the discharge date to the hospitalization ward or death date.

Patients older than 18 years old undergoing elective or emergency cardiac surgery (valvular, coronary, aortic) were included (those in whom the indication for surgery occurred during admission). Patients who died within the first 24 h after surgery, emergency surgery, or due to endocarditis (including cardiac transplantation and aortic dissection) and surgery without ECC were excluded.

Demographic data, comorbidities, chronic therapies used, Euroscore (European System for Cardiac Operative Risk Evaluation), ECC time, ischemia time, use of blood products, the length of ICU stay, need for treatment with vasoactive drugs (VAD), or support with ventricular assist devices, and pre- and postoperative analytical data were

recorded for each patient. Furthermore, complications during admission were recorded: development of cardiac arrhythmias, acute kidney failure, need for mechanical ventilation (MV) for > 48 h, presence of nosocomial infections, polytransfusion, need for reintervention, surgical wound infection, and death. Acute and acute-on-chronic kidney failure were defined in full compliance with criteria of the Acute Kidney Injury Network (AKIN).¹⁰ Furthermore, patients were categorized into those with kidney failure without need for renal replacement therapy (RRT) and those who actually did. Neurological complication was defined as the occurrence of postoperative neurological focal deficits or persistent coma or stupor and/or presence of seizures. Infectious complications were defined using the criteria established by ENVIN-HELICS.¹¹ Postoperative respiratory failure was defined as respiratory failure due to postoperative complications that required ICU admission or prolonged ICU stays with ventilatory support (whether invasive and/or non-invasive). Postoperative acute hepatic dysfunction was defined as doubling of the upper normal limit of transaminases associated with evidence of liver failure (jaundice and/or coagulopathy) in a patient without chronic liver disease. Paralytic ileus was defined as decreased GI motility 48 h after surgery, preventing the introduction of enteral nutrition, and mesenteric ischemia as a reduced blood flow to the intestines, whether abruptly or progressively. ICU mortality beyond the first 24 h after admission was recorded as well.

The state of shock immediately after surgery shock was categorized as follows:

- 1 Vasoplegic shock: systemic arterial hypotension (MAP < 65 mmHg) due to intense vasodilation, with SVR (< 800 dynes/cm⁵) and normal or elevated CI (> 2.2 L/min/m²) in the absence of acute cardiac dysfunction and active infection, characterized by an inadequate (reduced) response to standard doses of vasopressor drugs. Refractory dose of vasopressor drug was defined as an infusion of NAD > 0.5 µg/kg/min of NAD base; equivalent to 1 µg/kg/min of NAD bitartrate, initiating the gradual infusion of VSP doses with up-titration of 0.01–0.02 IU/h up to a maximum dose of 2 IU/h, according to hemodynamic response.
- 2 Post-cardiotomy cardiogenic shock, defined as acute heart failure, with decreased cardiac output (CO) resulting in tissue hypoperfusion, with CI < 2 L/min/m², systolic blood pressure (SBP) < 90 mmHg, and SVR within normal values. It includes uni- or biventricular cardiac dysfunction, perioperative acute myocardial infarction (AMI), and acute valvular dysfunction.¹²

In the descriptive analysis, continuous variables were expressed as mean ± standard deviation, median and interquartile range, and the categorical ones as absolute value of cases and percentage. Kolmogorov–Smirnov normality contrast test was used too.

In the inferential analysis, for comparison of means, the Student's *t*-test or one-way ANOVA was used to compared more than 2 groups, while the comparative analysis of proportions was conducted using the chi-square test. Yates correction or Fisher's exact test were used, when necessary.




Figure 1 Included and excluded patients.

We performed a multivariate analysis through binary logistic regression. In the binary logistic regression analysis, variables that were associated with the occurrence of vasoplegia in the univariate analysis and those considered of clinical interest were included. *P* values < .05 were considered statistically significant. Statistical analysis was performed using the SPSS version 20 statistical software package.

Results

From January 1, 2021, to December 31, 2022, 3631 patients were treated in the Intensive Care Unit (ICU) of Hospital Universitario Miguel Servet, of which 895 cases (24.6%) required cardiac surgery. Of these, 122 patients were excluded from the analysis for not meeting inclusion criteria (Fig. 1).

A total of 773 patients were included in the study, with a median age of 70 years [62–75] and a predominance of male patients (65.7%). It was a population with multiple cardiovascular risk factors (Table 1), highlighting the presence of preoperative pulmonary hypertension (PHT) in 35.6% of the analyzed population.

Post-ECC vasoplegia was documented in 12.2% of the cases (94 patients), with a predominance of female patients ($P < .0001$), an older population ($P = .001$), type of surgery ($P = .022$), and with the presence of preoperative PHT ($P < .0001$), as well as in the subgroup of patients where methicillin-resistant *Staphylococcus aureus* (MRSA) was detected in the preoperative epidemiological control swab ($P = .028$) (Table 1).

The occurrence of vasoplegia was associated with a greater need for platelet transfusion ($P = .001$), fresh frozen plasma ($P = .001$), fibrinogen ($P = .003$), and prothrombin complex ($P < .0001$) (Table 2).

Binary logistic regression analysis showed a statistically independent positive association with age (OR, 1.036; 95%CI,

1.008–1.064; $P = .010$), female gender (OR, 2.56; 95%CI, 1.569–4.179; $P < .0001$), preoperative creatinine levels (OR, 1.388; 95%CI, 1.019–1.893; $P = .038$), ECC times (OR, 1.009; 95%CI, 1.003–1.016; $P = .007$), lactic acid level upon ICU admission (OR, 1.33; 95%CI, 1.069–1.654; $P = .010$), and the need for prothrombin complex transfusion during surgery (OR, 1.733; 95%CI, 1.013–2.963; $P = .045$). On the other hand, higher preoperative systolic blood pressure values acted as an independent protective factor (OR, 0.975; 95%CI, 0.961–0.990; $P = .001$) (Table 3).

Similarly, the occurrence of vasoplegia was associated with higher rates of medical and surgical complications after admission to the ICU (Table 4).

Regarding the group of patients who developed vasoplegia ($n = 94$), 18 of them required the administration of VSP as bailout therapy in the immediate postoperative period, with a statistically significant association with the use of ACEIs, aldosterone antagonists, and SGLT2i prior to surgical intervention. Additionally, these patients had worse EuroScore scores ($P = .017$), longer ECC times ($P = .011$), and higher lactic acid levels upon the ICU admission ($P < .0001$). Finally, patients who experienced refractory vasoplegia and required bailout VSP exhibited more complications, the intraoperative transfusion of blood products, consumption of technical resources, longer ICU stays and higher mortality rates (44.4% vs 2.6%; $P < .0001$) (Table 5).

Discussion

Post-ECC vasoplegia is a serious and frequent condition, with incidence rates ranging from 5% up to 25%,^{2,3,13,14} reaching up to 44% in some series,^{3,15,16} and associated with high mortality (25%–50%).^{1,17} In our series, the detected prevalence is 12.2%, associated with a lower overall mortality than the one documented in other series (10.6%).

Table 1 Demographic, Epidemiological, comorbidities, and chronic treatment data.

	Total		Vasoplegia				P
	N = 773		Yes (n = 94)		No (n = 679)		
	n	%	n	%	n	%	
Age (Mean ± SD)	67.3 ± 10.9		69.8 ± 8.9		66.0 ± 11.0		.001
Sex:							
Woman	265	34.30%				31.80%	.000
Past medical history							
AHT	531	68.70%	69	73.40%	462	68.00%	ns
Dyslipidemia	493	63.80%	54	57.40%	439	64.70%	ns
Diabetes mellitus	234	30.30%	28	29.80%	206	30.30%	ns
Smoking	326	42.20%	34	36.20%	292	43.00%	ns
CKD	133	17.20%	15	16.0%	118	17.40%	ns
Ejection fraction:							ns
+EF < 50%	133	17.20%	16	17.0%	117	17.20%	
Postoperative PHT	278	36.00%	49	52.10%	229	33.70%	.000
Previous therapy							
ACEIs/ARBs II	473	61.20%	51	54.20%	422	62.20%	ns
Beta-blockers	412	53.30%	49	52.10%	363	53.50%	ns
Statins	435	56.30%	52	55.30%	383	56.40%	ns
Calcium antagonists	148	19.10%	23	24.50%	125	18.40%	ns
Aldosterone antagonists	133	17.20%	18	19.10%	115	16.90%	ns
Sacubitril valsartan	19	2.60%	1	1.10%	19	2.80%	ns
SGLT2 inhibitors	97	12.50%	13	13.80%	84	12.40%	ns
Sildenafil	13	1.70%	1	1.10%	12	1.80%	ns
Microbiological history							
MRSA detection	17	2.20%	5	5.30%	12	1.80%	.028
Type of surgery							
Isolated or combined aortic valve repair (valve and/or coronary artery)	72	9.70%	6	6.40%	66	9.70%	.022
Isolated or combined aortic valve repair ^a	518	67.00%	75	79.80%	443	65.20%	
Isolated coronary artery repair ^a	168	21.70%	11	11.70%	157	23.10%	
Other	15	1.90%	2	2.10%	13	1.90%	

AHT, arterial hypertension; CKD, chronic kidney disease; EF, ejection fraction; MRSA, methicillin-resistant *Staphylococcus aureus*; PHT, pulmonary hypertension.

^a P = .007.

The medical literature identifies multiple risk factors related to this condition, such as male sex,^{4,13,15,18} advanced age,^{2,3,13,18} higher EuroScore scores,¹⁸ preoperative use of ACEIs,^{5,19} or extended ECC times. Our data are consistent with those published regarding age, having shown an independent association.

Regarding sex, however, we saw a predominance in females, behaving as an independent predictor for the development of vasoplegia. This is consistent with that published by Mesa et al.²⁰

In our study, no statistically significant association was seen between the development of vasoplegia and the EuroScore score. However, the subgroup of patients with vasoplegia who received treatment with VSP had higher scores with a statistically significant association. This scale provides a simple assessment of perioperative mortality risk in cardiac surgery.²¹ In the medical literature, EuroScore has been related to vasoplegia in univariate analyses, with

the statistical significance disappearing in the multivariate analyses.^{13,14} In this work, it was included in the multivariate analysis without observing statistical significance; therefore, we cannot consider it an adequate predictor of postoperative vasoplegia.

Regarding perioperative drug treatment, the meta-analysis conducted by Noubiac et al.²² of 10 observational case-control studies showed that the use of ACEIs and ARBs poses an independent risk factor for the development of post-ECC vasoplegia. However, our results do not reveal such a relationship. They have even been considered a protective factor vs the development of NAD refractory vasoplegia in the group of patients who developed it. This finding might seem paradoxical at first glance; however, it should be noted that patients categorized as chronic users of ACEIs and/or ARBs II discontinued the drug within the 48 h prior to the intervention to prevent this condition, as recommended by some authors.¹⁵ The abrupt withdrawal of ACEIs

Table 2 Perioperative data.

	Total		Vasoplegia				<i>P</i>
	N = 773		YES (n = 94)		No (n = 679)		
	Mean	SD	Mean	SD	Mean	SD	
Total EuroScore	2.56	2.58	2.96	2.12	2.5	2.64	ns
Preoperative BP (mmHg)	124	16	119	14	125	16	.001
Preoperative creatinine levels (mg/dL)	1.09	0.67	1.18	0.6	1.07	0.68	ns
Preoperative hematocrit (%)	41	5.1	40.3	5.3	41.1	5.1	ns
ECC time (min)	101	36	117	39	99	35	.000
Ischemia time (min)	73	30	82	33	72	29	.006
Platelet at the ICU admission (x nL)	149	71	173	76	146	70	.000
Hemoglobin at the ICU admission (g/dL)	10.3	1.4	9.5	1	10.4	1.4	.000
Fibrinogen at the ICU admission (g/L)	2.2	2.9	2.2	2.9	2.2	2.9	ns
Lactic acid at the ICU admission (mmol/L)	1.8	0.9	2.2	1.5	1.7	0.8	.001
Transfusion needs							
Red blood cells (no. of concentrates)	152	19.70%	23	24.50%	129	19.00%	ns
Platelets (pool no.)	398	51.50%	63	67.00%	335	49.30%	.001
Fibrinogen (g)	229	29.60%	40	42.60%	189	27.80%	.003
Prothrombin complex	188	24.3%	40	42.6%	148	21.8%	.000
Frozen fresh plasma (n)	8	1.00%	4	4.30%	4	0.60%	.001
Factor VIIa	11	1.40%	2	2.10%	9	1.30%	ns

Table 3 Variables with an independent association with post-ECC vasoplegia.

	OR	95%CI		P
Age	1036	1008	1064	.01
Sex (woman)	256	1569	4179	.000
Preoperative BP	0975	0961	099	.001
Preoperative creatinine	1388	1019	1893	.038
EC time	1009	1003	1016	.007
Lactic acid at the ICU admission	133	1069	1654	.01
Prothrombin complex transfusion	1733	1013	2963	.045

Variables introduced: age, gender, total EuroScore, preoperative blood pressure, preoperative creatinine, preoperative hematocrit, ECC time, ischemia time, lactic acid at the ICU admission, preoperative pulmonary arterial hypertension (PAH), ejection fraction < 50%, platelet transfusion requirement, fibrinogen transfusion requirement, prothrombin complex requirement, MRSA detection, type of surgery.

and/or ARBs II leads to a rapid elevation of blood pressure within the first few days.^{23,24} This phenomenon could justify our results, where higher preoperative systolic blood pressure values constituted an independent protective factor for the development of post-ECC vasoplegia, as reflected in the cumulative evidence.^{2,15,25} Therefore, chronic users of ACEIs/ARBs II may experience a reflex elevation of their blood pressure values upon discontinuation of treatment, resulting in a lower incidence of vasoplegia. We have not found in the literature ANY studies whose design takes this measure into account in the incidence of post-ECC vasoplegia.

PHT is an independent risk factor for mortality in cardiac surgery.²⁶ It is included in various surgical risk prediction models (including the Euroscore²¹) as one of the

most significant factors for the occurrence of postoperative vasoplegia.²⁰ A study published in 2018 found that numerous variables related to pulmonary hemodynamics (pressure in the pulmonary artery trunk, pressure in the right atrium, pulmonary vascular resistance), when increased preoperatively, were related to the postoperative occurrence of vasoplegia. In our study, the presence of preoperative PHT has been associated with the development of vasoplegia.

The duration of ECC is one of the factors most widely associated with this condition.^{13,15} ECC induces the release of inflammatory mediators (cytokines, interleukins) that predispose to the development of vasoplegia, and additionally, it excludes pulmonary circulation. This results in a decreased catabolism of vasodilatory molecules, such as bradykinin, which is synthesized in the pulmonary alveoli.

Table 4 Medical and surgical complications at the ICU admission.

	Total		Vasoplegia				P
	N = 773		Yes (n = 94)		No (n = 679)		
	n	%	n	%	n	%	
Acute kidney injury	146	18.90%	35	37.20%	111	16.30%	.000
Exacerbated CKD	65	8.40%	15	16.00%	50	7.40%	.005
Reintervention	22	2.80%	9	9.60%	13	1.90%	.000
Bacteremia	7	0.90%	5	5.30%	2	0.30%	.000
MV-associated pneumonia	8	1.00%	7	7.40%	1	0.10%	.000
Surgical site infection	2	0.30%	0	0.00%	2	0.30%	ns
Mesenteric ischemia	0	0.00%	0	0.00%	0	0.00%	ns
Postoperative ileum	14	1.80%	5	5.30%	9	1.30%	.007
Multi-drug resistant colonization	15	1.90%	6	6.40%	9	1.30%	.001
Multi-drug resistant infection	1	0.10%	1	1.10%	0	0.00%	.007
Neurological complications	26	3.40%	9	9.60%	17	2.50%	.000
Respiratory infection	57	7.40%	13	13.80%	44	6.50%	.011
Liver failure	3	0.40%	2	2.10%	1	0.10%	.004
Death	19	2.50%	10	10.60%	9	1.30%	.000
Need for vasoactive support and blue methylene							
Noradrenaline	461	59.60%	94	100%	368	54.20%	.000
Dobutamine	626	81.00%	81	86.20%	545	80.30%	Ns
Vasopressin	23	3.00%	18	19.10%	5	0.70%	.000
Blue methylene	3	0.40%	3	3.20%	0	0.00%	.002
Need for renal replacement therapy (RRT) and VA-ECMO							
RRT	15	1.90%	8	8.50%	7	1.00%	.000
VA-ECMO	3	0.40%	2	2.10%	1	0.10%	.004
Time on MV (hours)	Median		Median		Median		
	5.9 [4.3–8.2]		7.2 [5.0–13.0]		5.8 [4.3–7.9]		.004
Length of ICU stay (days)	Mean	SD	Mean	SD	Mean	SD	
	5.15	10.3	10.97	15.6	4.35	9.06	.000
Mortality	n	%	n	%	n	%	
	19	2.50%	10	10.60%	9	1.30%	.000

AHT, arterial hypertension; CKD, chronic kidney disease; MV, mechanical ventilation; RRT, renal replacement therapy; VA-ECMO, veno-arterial extracorporeal membrane oxygenation.

Consequently, there is a plasma increase of vasodilatory components followed by a decrease in vasoconstrictive components, disrupting the natural balance of vasomotor tone.¹⁶

In our population, longer surgical times (both ECC time and ischemia time) have been associated with the onset of vasoplegia and the need for bailout VSP in the group of patients with vasoplegia. There was a statistically significant association with the type of surgery, but it disappeared in the logistic regression analysis, justified by the greater importance of ECC time in more complex surgeries.

Regarding intraoperative and immediate postoperative factors at the ICU setting, we have found that lower hemoglobin levels are associated with a higher risk of vasoplegia, which has been previously described in some studies. Additionally, the meta-analysis conducted by Dayan et al.¹⁵ concludes that both intraoperative hemorrhage and/or hemorrhagic shock, as well as the transfusion of plasma components have been associated with post-ECC vasoplegic shock. Such data are reinforced by our findings, as we have demonstrated that the need for prothrombin complex transfusion during surgical intervention has proven to

be an independent risk factor for the development of post-ECC vasoplegia. Both the nature of the components of the prothrombin complex and the situations of massive bleeding in which its administration is indicated can trigger an inflammatory response and consequently, vasoplegic shock.

There are no solid recommendations to guide the management of post-ECC vasoplegia. Catecholamines are considered the first-line therapy. NAD has alpha-1 effects with direct action on vascular tone. Among its side effects are arrhythmic and ischemic events at myocardial and other organ levels; however, these are dose-dependent. Its safety profile is well-known, being safe at low doses (<0.3 µg/kg/min). Recent studies support the use of VSP⁵ or agents such as methylene blue, hydroxocobalamin, corticosteroids, or angiotensin II.²⁷ Among them, VSP has demonstrated its efficacy in significant works, being used as a bailout therapy to treat distributive shock.^{5,6} In the context of post-ECC vasoplegic shock, its use aims to reverse the loss of vascular tone in patients undergoing cardiac surgery who remain unresponsive to the usual therapeutic measures.^{4,28} Observational studies describe the beneficial

Table 5 Patients with post-ECC vasoplegic shock. Factors associated with and increased severity and need for VSP therapy. Prognosis of post-ECC vasoplegia.

Preoperative clinical variables	Total (Vasoplegia)		Vasopressin				P
	N = 94		Yes (n = 18)		No (n = 76)		
Age (Mean ± SD)	69.8 ± 8.9		71.7 ± 5.4		69.4 ± 9.5		ns
	n	%	n	%	n	%	
Woman	49	52.10%	8	44.40%	41	53.90%	ns
Past medical history							
AHT	69	73.40%	13	72.20%	56	73.70%	ns
Dyslipidemia	54	57.40%	9	50.00%	45	59.20%	ns
Diabetes mellitus	28	29.80%	5	27.80%	23	30.30%	ns
Smoking	34	36.20%	9	50.00%	25	32.90%	ns
CKD	15	16.00%	1	5.60%	14	18.40%	ns
EF:							ns
+EF < 50%	16	17.10%	3	16.70%	12	15.80%	
Preoperative PHt	49	52.10%	8	44.40%	41	53.90%	ns
Previous therapy							
ACEIs / ARBs II	51	54.20%	5	27.80%	46	60.50%	.012
Beta-blockers	49	52.10%	6	33.30%	43	56.50%	ns
Statins	52	55.30%	8	44.40%	44	57.90%	ns
Calcium antagonists	23	24.50%	4	22.20%	19	25%	ns
aldosterone antagonists	18	19.10%	0	0.00%	18	23.70%	.023
Sacubitril Valsartan	1	1.10%	0	0.00%	1	1.40%	ns
SGLT2 inhibitors	13	13.80%	5	27.80%	8	10.50%	.048
Sildenafil	1	1.10%	0	0.00%	1	1.40%	ns
Microbiological history							
MRSA detection	5	5.30%	1	5.60%	4	5.30%	ns
Perioperative variables	Mean	SD	Mean	SD	Mean	SD	P
EuroScore	2.96	2.12	4.02	2.41	2.71	1.98	.017
Preoperative BP (mmHg)	119	14	115	12	120	14	ns
Preoperative creatinine (mg/dL)	1.18	0.6	1.42	0.87	1.13	0.51	
Preoperative hematocrit (%)	40.3	5.3	40.8	5.2	40.2	5.3	ns
EC time (min)	117	39	142	46	110	34	.011
Ischemia time (min)	82	33	96	46	79	29	ns
Platelet at the ICU admission (x nL)	173	76	175	93	173	72	ns
Hemoglobin at the ICU admission (g/dL)	9.5	1	9.2	1.2	9.6	0.9	ns
Fibrinogen at the ICU admission (g/L)	2.2	2.9	3	2.7	2	2.9	ns
Lactic acid at the ICU admission (mmol/L)	2.2	1.5	3.6	2.7	1.9	0.8	<.001
Need for the intraoperative transfusion of hemoderivatives	n	%	n	%	n	%	P
Red blood cells	23	25.5	8	44.4	15	19.7	.028
Platelets	63	67.0	16	88.9	47	61.8	.028
Fibrinogen	40	42.6	9	50	31	40.8	Ns
Prothrombin complex	40	42.60%	13	72.20%	27	35.5	.005
Frozen fresh plasma	4	4.3	2	11.1	2	2.6	ns
Factor VIIa	2	2.1	1	5.6	1	1.3	ns
Complications during the ICU stay	n	%	n	%	n	%	P
Acute kidney injury	35	37.2%	10	55.6%	25	32.9%	ns
Exacerbated CKD	15	16.0%	6	33.3%	9	11.8%	.025
Reintervention	9	9.6%	6	33.3%	3	3.9%	<.001
Bacteremia	5	5.3%	2	11.1%	3	3.9%	Ns
MV-associated pneumonia	7	7.4%	5	27.8%	2	2.6%	<.001
Surgical site infection	94	100%	18	100%	76	100%	Ns
Postoperative ileum	5	5.3%	1	5.6%	4	5.3%	Ns
Mesenteric ischemia	0	0.0%	0	0.0%	0	0.0%	Ns

Table 5 (Continued)

Preoperative clinical variables	Total (Vasoplegia)		Vasopressin				<i>P</i>
	N = 94		Yes (n = 18)		No (n = 76)		
Age (Mean ± SD)	69.8 ± 8.9		71.7 ± 5.4		69.4 ± 9.5		ns
	n	%	n	%	n	%	
Multi-drug resistant colonization	6	6.4%	1	5.6%	5	6.6%	Ns
Multi-drug resistant infection	1	1.1%	0	0.0%	1	1.3%	Ns
Neurologic complications	9	9.6%	5	27.8%	4	5.3%	.004
Respiratory distress	13	13.8%	5	27.8%	8	10.5%	Ns
Liver failure	2	2.1%	2	11.1%	0	0.0%	.003
Need for RRT, VA-ECMO	n	%	n	%	n	%	<i>P</i>
RRT	8	8.5%	5	27.5%	3	3.9%	.001
VA-ECMO	2	2.1%	1	5.6%	1	1.3%	ns
Time on MV (hours)	Median		Median		Median		
	7.2 [5.0–13.0]		54.9 [23.8–251.0]		6.1 [4.6–9.0]		<.001
Length of ICU stay (days)	Mean	SD	Mean	SD	Mean	SD	<i>P</i>
	10.97	15.6	19.49	19.43	8.95	13.95	.009
Mortality	n	%	n	%	n	%	<i>P</i>
	10	10.6%	8	44.4%	2	2.6%	<.001

AHT, arterial hypertension; CKD, chronic kidney disease; EF, ejection fraction; MV, mechanical ventilation; RRT, renal replacement therapy; VA-ECMO, veno-arterial extracorporeal membrane oxygenation.

hemodynamic effects of VSP at low doses in patients with post-cardiotomy shock.^{29–31}

In the VANCS controlled trial,⁵ patients with post-ECC vasoplegic shock were randomized into 2 groups to receive either NAD or VSP (both drugs as monotherapy). Therefore, the effect of the standard of care for this condition could not be evaluated: initial NAD and addition of bailout VSP (which is the clearest and most common indication for VSP in critically ill patients).^{32–34}

Another interesting characteristic of VSP therapy in patients undergoing cardiac surgery is its neutral effect on myocardial oxygen consumption.⁵ The VANCS trial demonstrated that VSP does not induce an increased heart rate and is not associated either with an increased incidence of myocardial ischemia.^{5,8}

VSP can cause ischemia and necrosis; however, this occurs at doses higher than its therapeutic range (>3.6 IU/h).^{9,35} In fact, in our study, there were no serious ischemic complications in the VSP group at the doses used. However, the group of patients with refractory vasoplegia who needed bailout VSP showed higher morbidity rates and more complications vs patients whose vasoplegic shock could be controlled with low doses of NAD (<0.25 μ g/kg/min NAD base). In this regard, the refractory vasoplegia that prompted the use of VSP may have implied a higher degree of organ failure, which is the cause of the increased morbidity and mortality observed in this group.

One of the strengths of our study is that the hemodynamic profile of shock has been clearly defined, classifying post-ECC vasoplegia as patients in shock with normal or elevated cardiac output (determined by echocardiography and/or invasive hemodynamic monitoring) ($CI > 2.2$ L/min/m²), low systemic vascular resistances ($SVR < 800$ dynes/s/cm⁵), and no evidence of hypovolemia or active infection.

A major limitation in the published literature on the management of this condition lies in how post-ECC vasoplegia has traditionally been defined. Loose criteria have been used to determine the hemodynamic variables that define it, categorizing it as a nonspecific postoperative shock after a cardiac intervention with extracorporeal surgery.³⁶ Consequently, the predominant type of shock (cardiogenic and/or vasoplegic) has often not been differentiated. The recent meta-analysis conducted by Noubiap et al. with more than 15 000 recruited patients explicitly acknowledges the use of lax hemodynamic criteria to define post-ECC vasoplegic shock.²² This fact may have led to a variable degree of imprecision in the evaluation and comparison of vasoactive agents in the management of post-ECC vasoplegia. In other words, studies have been designed with molecules affecting vascular tone in shock scenarios with possible cardiogenic (and even hypovolemic) components, which could diminish the robustness of their results.

The therapeutic approach used in our work is consistent with the latest recommendations and expert consensus,^{37,38} advocating for the initiation of NAD and, in more severe cases, the addition of VSP. Furthermore, there is currently no recommendation on the threshold dose of NAD as the mark that jumpstarts VSP therapy, with this dose varying from 0.1 μ g/kg/min to 0.7 μ g/kg/min across the different studies that have analyzed this issue.^{38,39} Therefore, another strength of our study is that this threshold was pre-established at doses of 0.5 μ g/kg/min of NAD base.

The main limitation of this study is its observational design, thus demonstrating association rather than causality. The low number of patients requiring VSP, the single-center nature of the study, the lack of collection of intraoperative variables such as septal temperature, the composition and quantity of cardioplegic solution, or not classifying the “refractory” profile associated with the administration of

NAD (requiring a rapid and exponential increase in its dose) vs the controlled profile (progressive increase in NAD until reaching a plateau without associated side effects)⁴⁰ are other limitations of our study that should be considered in future studies.

Conclusions

Post-ECC vasoplegia is associated with a higher mortality rate and development of complications. Shortening ECC time and reducing transfusions could minimize the risk of vasoplegia. ACEIs/ARBs discontinuation medical prior to surgery could reduce the need for VSP.

Vasopressor support with low-dose NAD is still considered first-line therapy, being VSP a good addition in refractory situations instead of having to up-titrate NAD (NAD ≥ 0.5 $\mu\text{g/kg/min}$ of basal NAD).

Authors' contributions

All authors declare that they have collaborated significantly in the design and development of this study, approved the submitted document, and taken responsibility for its contents.

Conflicts of interest

None declared.

References

- Datt V, Wadhwa R, Sharma V, Virmani S, Minhas HS, Malik S. Vasoplegic syndrome after cardiovascular surgery: a review of pathophysiology and outcome-oriented therapeutic management. *J Card Surg.* 2021;36:3749–60.
- Fischer GW, Levin MA. Vasoplegia during cardiac surgery: current concepts and management. *Semin Thorac Cardiovasc Surg.* 2010;22:140–4.
- Ltaief Z, Ben-Hamouda N, Rancati V, Gunga Z, Marcucci C, Kirsch M, et al. Vasoplegic syndrome after cardiopulmonary bypass in cardiovascular surgery: pathophysiology and management in critical care. *J Clin Med.* 2022;11:6407.
- Argenziano M, Chen JM, Cullinane S, Garfein E, Weinberg AD, Smith CR, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. *J Thorac Cardiovasc Surg.* 1998;116:973–80.
- Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, Rhodes A, Landoni G, Osawa EA, et al. Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: the VANCs randomized controlled trial. *Anesthesiology.* 2017;126:85–93.
- Schmittinger CA, Torgersen C, Luckner G, Schröder DCH, Lorenz I, Dünser MW. Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. *Intensive Care Med.* 2012;38:950–8.
- Weis F, Kilger E, Beiras-Fernandez A, Nassau K, Reuter D, Goetz A, et al. Association between vasopressor dependence and early outcome in patients after cardiac surgery. *Anaesthesia.* 2006;61:938–42.
- Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. *New Engl J.* 2008;358:877–87.
- Russell JA. Vasopressin in septic shock. *Crit Care Med.* 2007;35:609–15.
- Levey AS, Eckardt K-U, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. *Kidney Int [Internet].* 2020;97:1117–29. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0085253820302337>
- Programa ENVIN-HELICS Manual de Cumplimentación del Estudio Nacional; 2020. Available from: https://hws.vhebron.net/envin-helics/Help/Manual_2020.pdf
- Pérez Vela JL, Llanos Jorge C, Duerto Álvarez J, Jiménez Rivera JJ. Manejo clínico del shock poscardiotomía en pacientes adultos. *Med Intensiva.* 2022;46:312–25.
- Tsiouris A, Wilson L, Haddadin AS, Yun JJ, Mangi AA. Risk assessment and outcomes of vasoplegia after cardiac surgery. *Gen Thorac Cardiovasc Surg.* 2017;65:557–65.
- Mora-Ordóñez JM, Curiel-Balsera E, Hernández-Sierra B, Sánchez-Llorente F. Factores predisponentes en la vasoplejía posoperatoria: Azul de metileno (réplica). *Med Intensiva.* 2007;31:529.
- Dayan V, Cal R, Giangrossi F. Risk factors for vasoplegia after cardiac surgery: a meta-analysis. *Interact Cardiovasc Thorac Surg.* 2019;28:838–44.
- Aguirre-Sánchez JS, Bucio-Reta E, Martínez-Ramírez L, López-Pineda DM, Santos-Martínez LE, Florez-Figueroa F. Síndrome vasopléjico. *Arch Cardiol Mex.* 2011;81 Supl. 2:58–63.
- Shanmugam G. Vasoplegic syndrome — the role of methylene blue. *Eur J Cardiothoracic Surg.* 2005;28:705–10.
- van Vessel ME, Palmen M, Couperus LE, Mertens B, Berendsen RR, Tops LF, et al. Incidence and predictors of vasoplegia after heart failure surgery. *Eur J Cardiothoracic Surg.* 2017;51:532–8.
- Gilbert M, Lema G. Cirugía cardíaca con circulación extracorpórea: Síndrome vasopléjico y vasopresina. *Rev Med Chil.* 2011;139:368–72.
- Mesa JEF, Kenia D, García MP, Cordero ÁMP, Elizabeth D, Vázquez D, et al. Predictores de bajo gasto cardíaco perioperatorio en pacientes operados de cirugía cardíaca valvular. *CorSalud.* 2018;10:286–93.
- Riera M, Carrillo A, Ibáñez J, Sáez De Ibarra JI, Fiol M, Bonnin YO. Valor predictivo del modelo EuroSCORE en la cirugía cardíaca de nuestro centro. *Med Intensiva.* 2007;31:231–6.
- Noubiap JJ, Nouthé B, Sia YT, Spaziano M. Effect of preoperative renin-angiotensin system blockade on vasoplegia after cardiac surgery: a systematic review with meta-analysis. *World J Cardiol.* 2022;14:250–9.
- Vaur L, Bobrie G, Dutrey-dupagne C, Dubroca I, Vaisse B. Short-term effects of withdrawing angiotensin converting enzyme inhibitor therapy on home self-measured blood pressure in hypertensive patients. *Am J Hypertens.* 1998;11:165–73.
- Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. *Nephrol Dial Transplant.* 2010;25:3977–82.
- Levin MA, Lin HM, Castillo JG, Adams DH, Reich DL, Fischer GW. Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. *Circulation.* 2009;120:1664–71.
- Lorenzo S. Síndrome de bajo gasto cardíaco en el posoperatorio de cirugía cardíaca. *Rev Uruguaya Cardiol.* 2020;35:385–94.
- Shahzad S, Aaron M, Klick J, Evans A. Vasoplegia after cardiovascular procedures—pathophysiology and targeted therapy. *J Cardiothorac Vasc Anesth.* 2018;32:1013–22.
- Martin W, Dünser M, Bouvet O, Hans Knotzer M, Nish Arulkumar M, Ludhmila Abrahao Hajjar M, et al. Vasopressin in cardiac surgery: a meta-analysis of randomized controlled trials. *J Cardiothorac Vasc Anesth.* 2018;32:2225–32.
- Dünser M, Mayr A, Stallinger A, Ulmer H, Ritsch N, Knotzer H, et al. Cardiac performance during vasopressin infusion in postcardiotomy shock. *Intensive Care Med.* 2002;28:746–51.

30. Dünser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. *Anesth Analg*. 2001;93:7–13.
31. Morales DLS, Gregg D, Helman DN, Williams MR, Naka Y, Landry DW, et al. Arginine vasopressin in the treatment of 50 patients with postcardiotomy shock. *Ann Thorac Surg*. 2000;69:102–6.
32. Mayr VD, Luckner G, Jochberger S, Wenzel V, Hasibeder WR, Dünser MW. Vasopressin als reservevasopressor. Behandlung ausgewählter kardiogener schockzustände. *Anaesthesist*. 2007;56:1017–23.
33. Dunser MW, Wenzel V, Mayr AJ, Hasibeder WR. Management of vasodilatory shock. *Drugs*. 2003;63:237–56.
34. Kunkes JH, Baker WL, Hammond JA, Gluck J. Vasopressin therapy in cardiac surgery. *J Card Surg*. 2019;34:20–7.
35. Andaluz-Ojeda D, Cantón-Bulnes M, Richter CP, Garnacho-Montero J. Fármacos vasoactivos en el tratamiento del shock séptico. *Med Intensiva*. 2022;46:26–37.
36. Cheng Y, Pan T, Ge M, Chen T, Ye J, Lu L, et al. Evaluation of vasopressin for vasoplegic shock in patients with preoperative left ventricular dysfunction after cardiac surgery: a propensity-score analysis. *Shock*. 2018;50:519–24.
37. Dunning J, Levine A, Ley J, Strang T, Lizotte DE, Lamarche Y, et al. The Society of Thoracic Surgeons Expert Consensus for the resuscitation of patients who arrest after cardiac surgery. *Ann Thorac Surg*. 2017;103:1005–20.
38. Guarracino F, Habicher M, Treskatsch S, Sander M. Vasopressor therapy in cardiac surgery—an experts’ consensus statement. *J Cardiothorac Vasc Anesth*. 2021;35:1018–29.
39. Levy B, Bastien O, Benjelid K, Cariou A, Chouihed T, Combes A, et al. Experts’ recommendations for the management of adult patients with cardiogenic shock. *Ann Intensive Care*. 2015;5:1–10.
40. Guerci P, Belveyre T, Mongardon N, Novy E. When to start vasopressin in septic shock: the strategy we propose. *Crit Care*. 2022;26:22–3.